Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Anesthesiology
|
May 1, 1992
Subjective and psychomotor effects of subanesthetic doses of propofol in healthy volunteers
J P Zacny, J L Lichtor, D W Coalson, et al.
Current Medical Research and Opinion
|
February 20, 2016
Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment
T Bell, J P Crown, I Lang, et al.
ESMO Open
|
March 19, 2025
Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial
N Harbeck, V Dieras, K A Gelmon, et al.
Oncogene
|
November 11, 1999
Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells
Z Aguilar, R W Akita, R S Finn, et al.
British Journal of Cancer
|
October 29, 2009
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
G E Konecny, R Glas, J Dering, et al.
ESMO Gastrointestinal Oncology
|
April 17, 2026
Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study
Y J Kim, P Merle, R S Finn, et al.
Breast Cancer Research and Treatment
|
January 12, 2019
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
H S Rugo, R S Finn, V Diéras, et al.
Investigational New Drugs
|
May 23, 2018
Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer
R S Finn, D H Ahn, M M Javle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 18, 2018
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases
N C Turner, R S Finn, M Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 24, 2018
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
H S Rugo, V Diéras, K A Gelmon, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Anesthesiology
|
May 1, 1992
Subjective and psychomotor effects of subanesthetic doses of propofol in healthy volunteers
J P Zacny, J L Lichtor, D W Coalson, et al.
Current Medical Research and Opinion
|
February 20, 2016
Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment
T Bell, J P Crown, I Lang, et al.
ESMO Open
|
March 19, 2025
Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial
N Harbeck, V Dieras, K A Gelmon, et al.
Oncogene
|
November 11, 1999
Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells
Z Aguilar, R W Akita, R S Finn, et al.
British Journal of Cancer
|
October 29, 2009
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
G E Konecny, R Glas, J Dering, et al.
ESMO Gastrointestinal Oncology
|
April 17, 2026
Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study
Y J Kim, P Merle, R S Finn, et al.
Breast Cancer Research and Treatment
|
January 12, 2019
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
H S Rugo, R S Finn, V Diéras, et al.
Investigational New Drugs
|
May 23, 2018
Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer
R S Finn, D H Ahn, M M Javle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 18, 2018
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases
N C Turner, R S Finn, M Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 24, 2018
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
H S Rugo, V Diéras, K A Gelmon, et al.
Page
of 3